الفهرس 
Introduction
Cancer biology and geneticsOnly 14 pages are availabe for public view
 |  | from | 119 |  |  |
| | | from | 119 | | |
Abstract
The therapeutic treatment strategies for patients with hepatocellular carcinoma (HCC) remain unsatisfactory, and novel methods are urgently required to treat HCC. Curcumin is an active component of turmeric, which is derived from the rhizomes of Curcuma longa. In this study, different concentrations of curcumin extract were used separately to treat human hepatocellular carcinoma (HCC) HepG2 cells. MTT assays were used to evaluate cell proliferation. Flow cytometrywas carried out to measure BCl2, caspase 3, cell apoptosis, and determine cell cycle progression. Real time-PCR was applied to determine the expression levels of FasL and Notch1. The results revealed that the down-regulation of BCl2 protein expression. Cell line viable cells were significant decreased after curcumin treatment as well as relative mRNA of Notch1 expression. Conversely, caspase 3, cell apoptosis and FasL mRNA expression were upregulated. Also, curcumin treatment induced a dose-dependent accumulation of HepG2 cells in subG1phase with accompanied losses from G0/G1 phase. The curcumin extract significantly inhibits the proliferation of HepG2 cells through cell cycle arrest and regulating apoptosis. The protective effect of curcumin may be due to suppressing of Notch1 expression